share_log

AI/ML Innovations Inc. Introduces Its Proprietary "Long ECG Neural Network"

AI/ML Innovations Inc. Introduces Its Proprietary "Long ECG Neural Network"

AI/ML Innovations Inc.推出其專有的 “長心電神經網絡”
Accesswire ·  05/06 20:30

Highlights:

亮點:

  • 100 million+ ECGs are performed annually in the USA.
  • AIML's proprietary "Long ECG Neural Net" reduces labeling of long ECGs from several days to under 5 minutes.
  • Provides unsurpassed accuracy, depth and insight into the cardiac data.
  • 美國每年進行超過1億次心電圖。
  • AIML專有的 “長心電神經網絡” 將長心電圖的標記從幾天縮短到不到5分鐘。
  • 爲心臟數據提供無與倫比的準確性、深度和洞察力。

VICTORIA, BC / ACCESSWIRE / May 6, 2024 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a leading company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is proud to introduce its proprietary Long ECG Neural Net (L-ECG NN). The L-ECG NN provides cardiologists, researchers, pharmaceuticals and others, with a fast, accurate and comprehensive tool for the in-depth analysis and feature extraction of ECGs.

不列顛哥倫比亞省維多利亞州/ACCESSWIRE/2024年5月6日/致力於收購和推進滿足緊急社會需求的人工智能/機器學習技術的領先公司AI/ML Innovations Inc.(“AIML” 或 “公司”)(OTCQB: AIML)(OTCQB: AIML)(FWB: 42FB)很自豪地推出其專有的長心電神經網絡(L-ECG NN)。L-ECG NN 爲心臟病專家、研究人員、藥物和其他人員提供快速、準確和全面的心電圖深度分析和特徵提取工具。

The Need for Improved Utilization of ECG Data

需要提高心電圖數據的利用率

  • "The ECG is the most commonly performed cardiovascular diagnostic procedure, with >100 million ECGs obtained annually in the United States."1 (AHA Journals)
  • Typical 24/48 hour-long ECGs, that are used in clinical trial, drug discovery, and specialist cases, take many days of effort for in-depth labeling, when relying on conventional, semi-automatic methods.
  • "Even for an experienced cardiologist, accurately interpreting the ECG for a patient with concurrent arrhythmias is challenging" ... "there is an urgent unmet need for an automated or assisted multilabel ECG diagnostic framework, supported by artificial intelligence technology."2 (The Lancet)
  • “心電圖是最常用的心血管診斷程序,在美國每年獲得超過1億張心電圖。”1 (AHA 期刊)
  • 當依賴傳統的半自動方法時,用於臨床試驗、藥物發現和專科病例的典型24/48小時心電圖需要花費很多天的時間才能進行深度標記。
  • “即使對於經驗豐富的心臟病專家來說,準確解釋同時患有心律失常的患者的心電圖也具有挑戰性”...“對由人工智能技術支持的自動化或輔助多標籤心電圖診斷框架的迫切需求尚未得到滿足。”2 (《柳葉刀》)

The L-ECG NN Feature Set Advantage

L-ECG 神經網絡功能集的優勢

AIML's Long ECG Neural Net displays many advantages over conventional methods of analyzing ECG data:

與傳統的心電數據分析方法相比,AIML 的長心電神經網絡具有許多優勢:

  • Accurate: The L-ECG NN was trained and tested on human ECG data, providing accurate labeling with minimal (2ms) error.
  • In-depth: Our proprietary AI analysis algorithm enables in-depth analysis and feature extraction of ECGs, allowing clinicians and researchers to quickly identify specific changes to the heartbeats of a long recording.
  • Versatile: Our advanced AI analysis algorithm provides deep analysis of ECGs from multiple sources (e.g., holters, sleep studies, clinical drug trials).
  • Comprehensive: While rudimentary traditional methods of ECG analysis only spot the R-peak, we label every waveform and its duration, providing comprehensive cardiac data insights.
  • Fast: We are able to label all ECG features within minutes for ECGs of any size, rather than in days, as is the present case.
  • Future potential: The L-ECG NN has the potential of using the features extracted to detect and predict cardiovascular diseases, and discovering new digital biomarkers for cardiac and chronic patients.
  • 準確:L-ECG NN 根據人體心電圖數據進行訓練和測試,提供準確的標籤,誤差最小(2 毫秒)。
  • 深入:我們專有的人工智能分析算法可以對心電圖進行深入分析和特徵提取,使臨床醫生和研究人員能夠快速識別長時間記錄中心跳的特定變化。
  • 多功能:我們先進的人工智能分析算法可對來自多個來源(例如心電圖、睡眠研究、臨床藥物試驗)的心電圖進行深入分析。
  • 全面:雖然基本的傳統心電圖分析方法只能發現 R 峯值,但我們會標記每個波形及其持續時間,提供全面的心臟數據見解。
  • 快速:對於任何大小的心電圖,我們能夠在幾分鐘之內標記所有心電圖特徵,而不是像目前的情況那樣在幾天內標記出來。
  • 未來潛力:L-ECG NN有可能利用提取的特徵來檢測和預測心血管疾病,併爲心臟和慢性患者發現新的數字生物標誌物。

Product Configurations

產品配置

The L-ECG NN is available for hardware integration (use in 1- Lead ECG wearable monitors, 1 or 3-lead Holter monitors, and more), or for use online.

L-ECG NN 可用於硬件集成(用於 1 導聯心電圖穿戴式監視器、1 或 3 導聯心電圖監視器等),也可以在線使用。

  • Available as a REST API, allowing developers to integrate L-ECG NN into third-party applications.
  • A web application for easy use, without technical knowledge.
  • 作爲 REST API 提供,允許開發人員將 L-ECG NN 集成到第三方應用程序中。
  • 無需技術知識即可輕鬆使用的 Web 應用程序。

Our Targeted Market Segments/Users

我們的目標細分市場/用戶

While the potential user base for our technology is both broad and deep, we have identified several potential market segments that represent our "path of least resistance" to market penetration. Some of these include:

儘管我們技術的潛在用戶群既廣泛又深入,但我們已經確定了幾個潛在的細分市場,這些細分市場代表了我們 “阻力最小的市場滲透之路”。其中一些包括:

  • Pharmaceuticals & Clinical Drug Trials
  • Device/ECG hardware companies (e.g. Holter monitors or patches)
  • Researchers
  • Cardiology specialists
  • 藥物和臨床藥物試驗
  • 設備/心電圖硬件公司(例如 Holter 監視器或補丁)
  • 研究人員
  • 心臟病專家

Future Development Plans

未來發展計劃

AIML has several plans for the expansion of both the potential use and the users of the L-ECG NN technology going forward. Some of these include:

AIML制定了多項計劃,以擴大未來L-ECG NN技術的潛在用途和用戶。其中一些包括:

  • Regulatory approval: FDA submission for approval as a medical device.
  • Online access: An incorporated User Interface (UI) for users to directly interact with the NN Store. Users will be able to directly upload their ECG data and have a full display of resulting graphs and labels to analyze and download.
  • Diagnosis: Training of the L-ECG NN to analyze ECGs for heart abnormalities to accelerate and automate diagnoses
  • Prediction: Accelerate and, eventually, automate the analysis of existing ECG databases to enable early detection and prediction of cardiovascular diseases (CVDs).
  • 監管機構批准:作爲醫療器械提交美國食品藥品管理局批准。
  • 在線訪問:內置的用戶界面 (UI),用戶可以直接與 NN 商店進行交互。用戶將能夠直接上傳他們的心電圖數據,並全面顯示生成的圖表和標籤以供分析和下載。
  • 診斷:訓練 L-ECG NN 以分析心電圖中是否存在心臟異常,從而加速和自動診斷
  • 預測:加速並最終自動分析現有心電圖數據庫,以實現心血管疾病(CVD)的早期發現和預測。

Paul Duffy, CEO of AI/ML Innovations Inc. added, "With this announcement AI/ML embarks on our next era of innovation. This groundbreaking Long ECG Neural Net technology has the potential to revolutionize ECG analysis, saving time and costs while enhancing patient care." Duffy continues "What I am truly excited about is the L-ECG signal processing algorithms and their versatility to extend to any signal data presenting distinctive traits that warrant identification and analysis. Our advanced Neural Net models now learn the hidden structure of a signal and classify important features to detect other conditions. We will begin to apply this proprietary Neural Net technology to all biometric signals opening entirely new untapped markets for AI/ML."

AI/ML Innovations Inc.首席執行官保羅·達菲補充說:“隨着這一宣佈,人工智能/機器學習開啓了我們的下一個創新時代。這種開創性的長心電神經網絡技術有可能徹底改變心電圖分析,節省時間和成本,同時增強患者護理。”達菲繼續說:“我真正興奮的是L-ECG信號處理算法及其多功能性,可以擴展到任何具有獨特特徵且值得識別和分析的信號數據。我們先進的神經網絡模型現在可以學習信號的隱藏結構,並對重要特徵進行分類以檢測其他情況。我們將開始將這種專有的神經網絡技術應用於所有生物識別信號,爲人工智能/機器學習開闢全新的未開發市場。”

1

1

2

2

About AI/ML Innovations Inc.

關於 AI/ML Innovations Inc.

AI/ML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through strategic partnerships with Health Gauge (95.2% owned by AIML), Tech2Heal (up to 22% ownership rights, with 12.44% currently owned by AIML), AI Rx Inc. (70% owned by AIML) and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AI/ML's shares are traded on the Canadian Securities Exchange under the symbol "AIML", the OTCQB Venture Market under "AIMLF", and the Frankfurt Stock Exchange under "42FB".

AI/ML Innovations Inc.調整了其業務運營,以利用新興的人工智能(AI)和機器學習(ML)領域,最初的投資重點是新興的數字健康和福祉公司,這些公司利用人工智能、機器學習、雲計算和數字平台推動變革性的醫療管理解決方案和整個健康連續體的精準支持交付。通過與Health Gauge(AIML持有95.2%的股權)、Tech2Heal(高達22%的所有權,目前由AIML持有12.44%的所有權)、AI Rx Inc.(AIML持有70%的股權)以及其他計劃中的增值投資,公司繼續利用不斷擴大的增長領域,使公司所有利益相關者受益。AI/ML的股票在加拿大證券交易所交易,代碼爲 “AIML”,OTCQB風險投資市場以 “AIMLF” 的形式交易,在法蘭克福證券交易所交易的代碼爲 “42FB”。

On behalf of the Board of Directors
Tim Daniels, Executive Chairman

代表董事會
蒂姆·丹尼爾斯,執行主席

For more information about AI/ML Innovations:
For detailed information please see AI/ML's website or the Company's filed documents at
For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com

有關 AI/ML 創新的更多信息:
有關詳細信息,請訪問AI/ML的網站或公司提交的文件,網址爲
欲了解更多信息,請致電 (778) 405-0882 或 info@aiml-innovations.com 與 Blake Fallis 聯繫

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

CSE及其監管服務提供商(該術語在CSE的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

For AI/ML Innovations Investors

致人工智能/機器學習創新投資者

Certain statements made in this press release that are not based on historical information are forward-looking statements that involve substantial known and unknown risks and uncertainties. This press release contains express or implied forward-looking statements relating to, among other things, AI/ML Innovations' expectations concerning management's plans, objectives, and strategies, including strategies for defending the Company's intellectual property. These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. AI/ML Innovations Inc. undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events, or circumstances or otherwise except as expressly required by applicable securities law. Further information regarding the uncertainties and risks can be found in the disclosure documents filed by AI/ML with the securities regulatory authorities, available at .

本新聞稿中發表的某些非基於歷史信息的陳述是前瞻性陳述,涉及大量已知和未知的風險和不確定性。本新聞稿包含與AI/ML Innovations對管理層計劃、目標和戰略(包括捍衛公司知識產權的戰略)的預期有關的明示或暗示的前瞻性陳述。這些陳述既不是承諾也不是擔保,但存在各種風險和不確定性,其中許多風險和不確定性是我們無法控制的,這可能導致實際結果與這些前瞻性陳述中設想的結果存在重大差異。提醒現有和潛在投資者不要過分依賴這些前瞻性陳述,這些陳述僅代表截至本文發佈之日。除非適用的證券法明確要求,否則AI/ML Innovations Inc. 沒有義務更新或修改本新聞稿中包含的信息,無論是由於新信息、未來事件或情況還是其他原因。有關不確定性和風險的更多信息,可以在AI/ML向證券監管機構提交的披露文件中找到,網址爲。

SOURCE: AI/ML Innovations Inc.

來源:AI/ML Innovations Inc.


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論